Silibinin appeared to target multiple cytokine (IFNγ, IL-1β, and TNF-α)-induced signaling pathways such as the signal transducer and activator of transcription 3 (STAT3) to ultimately lower COX2 and iNOS expression in lung cancer cells [35,36]. This evidence concerns the gene STAT3 and lung carcinoma.